Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.

<h4>Background</h4>Several studies have shown that metabolic surgery is associated with remission of diabetes and hypertension. In terms of diabetes, factors such as duration, insulin use, weight loss, and age have been shown to contribute to the likelihood of remission. Such factors hav...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Erik Stenberg, Richard Marsk, Magnus Sundbom, Johan Ottosson, Tomas Jernberg, Ingmar Näslund, Erik Näslund
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Acceso en línea:https://doaj.org/article/c96257936d024d08ac7cc0bfd96ab3f9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c96257936d024d08ac7cc0bfd96ab3f9
record_format dspace
spelling oai:doaj.org-article:c96257936d024d08ac7cc0bfd96ab3f92021-12-02T19:55:35ZRemission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.1549-12771549-167610.1371/journal.pmed.1003817https://doaj.org/article/c96257936d024d08ac7cc0bfd96ab3f92021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pmed.1003817https://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Several studies have shown that metabolic surgery is associated with remission of diabetes and hypertension. In terms of diabetes, factors such as duration, insulin use, weight loss, and age have been shown to contribute to the likelihood of remission. Such factors have not been determined for hypertension. The aim of this study was to evaluate factors associated with the remission and relapse of hypertension after metabolic surgery, as well as the risk for major adverse cardiovascular event (MACE) and mortality in patients with and without remission.<h4>Methods and findings</h4>All adults who underwent metabolic surgery between January 2007 and June 2016 were identified in the nationwide Scandinavian Obesity Surgery Registry (SOReg). Through cross-linkage with the Swedish Prescribed Drug Register, Patient Register, and Statistics Sweden, individual data on prescriptions, inpatient and outpatient diagnoses, and mortality were retrieved. Of the 15,984 patients with pharmacologically treated hypertension, 6,286 (39.3%) were in remission at 2 years. High weight loss and male sex were associated with higher chance of remission, while duration, number of antihypertensive drugs, age, body mass index (BMI), cardiovascular disease, and dyslipidemia were associated with lower chance. After adjustment for age, sex, BMI, comorbidities, and education, the cumulative probabilities of MACEs (2.8% versus 5.7%, adjusted odds ratio (OR) 0.60, 95% confidence interval (CI) 0.47 to 0.77, p < 0.001) and all-cause mortality (4.0% versus 8.0%, adjusted OR 0.71, 95% CI 0.57 to 0.88, p = 0.002) were lower for patients being in remission at 2 years compared with patients not in remission, despite relapse of hypertension in 2,089 patients (cumulative probability 56.3%) during 10-year follow-up. The main limitations of the study were missing information on nonpharmacological treatment for hypertension and the observational study design.<h4>Conclusions</h4>In this study, we observed an association between high postoperative weight loss and male sex with better chance of remission, while we observed a lower chance of remission depending on disease severity and presence of other metabolic comorbidities. Patients who achieved remission had a halved risk of MACE and death compared with those who did not. The results suggest that in patients with severe obesity and hypertension, metabolic surgery should not be delayed.Erik StenbergRichard MarskMagnus SundbomJohan OttossonTomas JernbergIngmar NäslundErik NäslundPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 18, Iss 11, p e1003817 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Erik Stenberg
Richard Marsk
Magnus Sundbom
Johan Ottosson
Tomas Jernberg
Ingmar Näslund
Erik Näslund
Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.
description <h4>Background</h4>Several studies have shown that metabolic surgery is associated with remission of diabetes and hypertension. In terms of diabetes, factors such as duration, insulin use, weight loss, and age have been shown to contribute to the likelihood of remission. Such factors have not been determined for hypertension. The aim of this study was to evaluate factors associated with the remission and relapse of hypertension after metabolic surgery, as well as the risk for major adverse cardiovascular event (MACE) and mortality in patients with and without remission.<h4>Methods and findings</h4>All adults who underwent metabolic surgery between January 2007 and June 2016 were identified in the nationwide Scandinavian Obesity Surgery Registry (SOReg). Through cross-linkage with the Swedish Prescribed Drug Register, Patient Register, and Statistics Sweden, individual data on prescriptions, inpatient and outpatient diagnoses, and mortality were retrieved. Of the 15,984 patients with pharmacologically treated hypertension, 6,286 (39.3%) were in remission at 2 years. High weight loss and male sex were associated with higher chance of remission, while duration, number of antihypertensive drugs, age, body mass index (BMI), cardiovascular disease, and dyslipidemia were associated with lower chance. After adjustment for age, sex, BMI, comorbidities, and education, the cumulative probabilities of MACEs (2.8% versus 5.7%, adjusted odds ratio (OR) 0.60, 95% confidence interval (CI) 0.47 to 0.77, p < 0.001) and all-cause mortality (4.0% versus 8.0%, adjusted OR 0.71, 95% CI 0.57 to 0.88, p = 0.002) were lower for patients being in remission at 2 years compared with patients not in remission, despite relapse of hypertension in 2,089 patients (cumulative probability 56.3%) during 10-year follow-up. The main limitations of the study were missing information on nonpharmacological treatment for hypertension and the observational study design.<h4>Conclusions</h4>In this study, we observed an association between high postoperative weight loss and male sex with better chance of remission, while we observed a lower chance of remission depending on disease severity and presence of other metabolic comorbidities. Patients who achieved remission had a halved risk of MACE and death compared with those who did not. The results suggest that in patients with severe obesity and hypertension, metabolic surgery should not be delayed.
format article
author Erik Stenberg
Richard Marsk
Magnus Sundbom
Johan Ottosson
Tomas Jernberg
Ingmar Näslund
Erik Näslund
author_facet Erik Stenberg
Richard Marsk
Magnus Sundbom
Johan Ottosson
Tomas Jernberg
Ingmar Näslund
Erik Näslund
author_sort Erik Stenberg
title Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.
title_short Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.
title_full Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.
title_fullStr Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.
title_full_unstemmed Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study.
title_sort remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: a swedish nationwide registry-based cohort study.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/c96257936d024d08ac7cc0bfd96ab3f9
work_keys_str_mv AT erikstenberg remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
AT richardmarsk remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
AT magnussundbom remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
AT johanottosson remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
AT tomasjernberg remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
AT ingmarnaslund remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
AT eriknaslund remissionrelapseandriskofmajorcardiovasculareventsaftermetabolicsurgeryinpersonswithhypertensionaswedishnationwideregistrybasedcohortstudy
_version_ 1718375868214018048